CA Patent

CA2481241C — Fused quinoxaline derivatives as inhibitors of akt activity

Assigned to Individual · Expires 2010-07-27 · 16y expired

What this patent protects

The present invention is directed to compounds comprising a ring-fused quinoxalinyl moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and metho…

USPTO Abstract

The present invention is directed to compounds comprising a ring-fused quinoxalinyl moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

Drugs covered by this patent

Patent Metadata

Patent number: CA2481241C
Jurisdiction: CA
Classification: —
Expires: 2010-07-27
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.